Ralpancizumab

Ralpancizumab

Monoclonal antibody
Type	?
Source	Humanized (from mouse)
Target	neural apoptosis-regulated proteinase 1
Clinical data
Other names	RN317
ATC code	none
Identifiers
CAS Number	1407495-04-8
ChemSpider	none
UNII	YB9L51E4MD
Chemical and physical data
Formula	C6422H9922N1730O2012S54
Molar mass	145289.36 g·mol^−1

Ralpancizumab (INN;[1] development code RN317) is a monoclonal antibody designed for the treatment of dyslipidemia.[2][3]

This drug was developed by Pfizer.

References

1. World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
2. "Ralpancizumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association..
3. Levisetti M, Joh T, Wan H, Liang H, Forgues P, Gumbiner B, Garzone PD (January 2017). "A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy". Clinical and Translational Science. 10 (1): 3–11. doi:10.1111/cts.12430. PMC 5351011. PMID 27860267.